Search PubMed⌕ Search

Biomedical subjects

C Bouffioux

Publications and source records attributed to C Bouffioux.

At least 55 records · Page 3Linked to original sources
PubMed1984

[Prostatitis].

Explore the source record for details and available documents.

Anti-Bacterial Agents↗
PubMed1984

Early adjuvant adriamycin in superficial bladder carcinoma.

A multi-center study was performed in 110 patients with superficial transitional cell carcinoma of the bladder. Adriamycin (50 mg/50 ml) was administered intravesically within 24 hours after transurethral resection of TA-T1 (0-A) bladder tumours. Instillation was repeated twice during the first week, then weekly during the first month and then monthly for 1 year. The tolerance was evaluated in these 110 patients and 29 patients presented with local side effects. In 24 of these patients the chemical cystitis was severe enough to drop them out of the study. No systemic side effect was observed. Recurrence was studied on 82 evaluable patients at 1 year of follow up and on 72 patients followed for 2-3 years (mean: 32 months). Of these 82 patients, 23 were primary cases and 59 recurrent. On all 82 patients, 50 did not show any recurrence after 1 year (61%) while 32 presented with one or more recurrences (39%). Of these recurrences, 27 were T1 tumor while 5 progressed to more invasive lesions. In patients that were free of recurrence during the first year, 80% remained tumour free during the 2-3 years follow up period. In patients developing one or more recurrences during the first year, only half of them presented further recurrences once the instillations were stopped. The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR or both factors.

Carcinoma, Transitional Cell↗
PubMed1983

Early adjuvant adriamycin in superficial bladder carcinoma.

A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder. Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors. Instillation was repeated twice during the first week, then weekly during the first month and afterwards monthly for 1 year. The tolerance was evaluated in these 110 patients, and 29 patients presented with local side-effects. In 24 of these patients chemical cystitis was severe enough for them to drop out of the study. No systemic side-effects were observed. Recurrence was studied in 82 evaluable patients after 1 year of follow-up and in 72 patients followed for 2-3 years (mean 32 months). Of the 82 patients studied after 1 year, 23 had primary and 59 recurrent disease. Of the 82 evaluable patients, 50 did not show any recurrence after 1 year (61%), while 32 presented with one or more recurrences (39%). Of these recurrences, 27 were T1 tumors while five progressed to more highly invasive lesions. In patients that were free of recurrence during the first year, 80% remained tumor-free during the 2- to 3-year follow-up period. Of the patients developing one or more recurrences during the first year, only 50% presented with further recurrence once the instillations were stopped. The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.

Carcinoma, Transitional Cell↗
PubMed1982

[The measurement of DNA in material obtained by cyto-puncture of the prostate. Diagnostic, prognostic and therapeutic value (author's transl)].

The results of the measurement of deoxyribonucleic acid (DNA) by absorption cytophotometry after Feulgen reaction, in smears of trans-rectal fine needle aspiration of prostate cancers are exposed. The histograms may be distributed in 3 categories: poorly, moderately and highly aneuploïds and heteroplöids. The correlation between the category of ploïdy and the cytological grade is fair but the measurement of DNA offers a diagnostic and prognostic refinement: it distinguishes, among the grade 2 cancers (moderately differenciated) tumours with different potential evolutivity. Repeated measurements in treated patients (with orchiectomy or estrogens) give objective criterias of therapeutical response. Following our experience, the persistence or the reappearance of important abnormalities in the histogram in a treated patient are objective and often premonitory signs of therapeutical escape which invite, even in the absence of clinical evidence of progression, to change the treatment.

DNA, Neoplasm↗